Cadilac Eye drops

Mechanism of action

Ketorolac inhibits key pathways in prostaglandin synthesis, which is crucial to its mechanism of action. It is a non-selective inhibitor of both COX-1 and COX-2 enzymes, though its clinical efficacy is primarily derived from COX-2 inhibition. The COX-2 enzyme is responsible for converting arachidonic acid to prostaglandins that mediate inflammation and pain. By blocking this pathway, ketorolac provides analgesia and reduces inflammation. The drug is administered as a racemic mixture, with the 'S' enantiomer being largely responsible for its pharmacological activity.

Pharmacodynamics

As a non-selective NSAID, ketorolac acts by inhibiting COX-1 and COX-2 enzymes, which convert arachidonic acid to prostaglandins. The COX-1 enzyme is constitutively active in various tissues such as platelets and gastric mucosa, while COX-2 is inducible and mediates inflammation, pain, and fever. Inhibition of COX-1 can result in adverse effects including increased bleeding risk and gastric ulceration, whereas the desired anti-inflammatory and analgesic effects are linked to the inhibition of COX-2. Therefore, while effective for pain management, ketorolac should not be used long-term due to the increased risk of serious adverse effects such as gastrointestinal bleeding, peptic ulcers, and perforations.

Pharmacokinetics

Ketorolac is rapidly absorbed following administration and reaches peak plasma concentrations within 1 to 2 hours. It is extensively protein-bound in plasma, primarily to albumin. The drug is metabolized in the liver through conjugation to glucuronic acid and is primarily excreted via the kidneys. The elimination half-life of ketorolac ranges from 5 to 6 hours in healthy individuals, and the pharmacokinetics may be altered in patients with renal impairment, necess

Contra-indications

• Active or history of peptic ulcer disease
• Severe renal impairment
• Hypersensitivity to ketorolac or other NSAIDs
• Concurrent use of other NSAIDs
• Pregnancy (third trimester)

Adverse effects

• Gastrointestinal bleeding
• Peptic ulcers
• Perforation of the gastrointestinal tract
• Renal toxicity
• Hepatic dysfunction
• Dizziness
• Headache
• Nausea
• Vomiting
• Rash
• Increased blood pressure

Interactions

• Increased risk of gastrointestinal bleeding with other NSAIDs or anticoagulants
• Potentially increased effects of methotrexate
• Increased serum levels of lithium
• May reduce the effectiveness of antihypertensive medications

Precautions

• Use with caution in patients with a history of gastrointestinal disease
• Monitor renal function, especially in elderly patients
• Caution in patients with asthma, as bronchospasm may occur
• Avoid use in patients with dehydration or hypovolemia

Pregnancy

Ketorolac should be avoided during pregnancy, particularly in the third trimester, due to the risk of fetal harm.

Breast-feeding

It is not known whether ketorolac is excreted in human milk. Caution is advised when administered to nursing women.

Storage

Store at room temperature, away from moisture and heat. Protect from light.

Formulations

• Oral tablet
• Injection solution

Indications

• Used in ophthalmic solutions to maintain pH levels
• Formulated in injectable preparations to enhance stability
• Buffering agent in various pharmaceutical formulations

Dosage

Children: Refer to specific product information for dosing instructions, as tromethamol is generally used as a component in formulations rather than as a standalone medication.

Adults: Refer to specific product information for dosing instructions, as tromethamol is generally used as a component in formulations rather than as a standalone medication.

Mechanism of action

Tromethamol functions as a proton acceptor, neutralizing acidic environments by raising the pH. This buffering action helps to stabilize the pH of solutions, making it suitable for use in formulations that require a specific pH range to maintain drug stability and effectiveness. It interacts with hydrogen ions in solution, thereby altering the ionic state of other active ingredients.

Pharmacodynamics

Tromethamol does not have direct pharmacological effects in the body as it is primarily used as a stabilizing agent. Its role in maintaining pH levels ensures that other active compounds remain effective. The pharmacodynamics are largely dependent on the active ingredients it is combined with, as it does not exert therapeutic effects on its own.

Pharmacokinetics

The pharmacokinetics of tromethamol are not well-studied as it is used mainly for its buffering properties rather than as an active therapeutic agent. It is generally considered to be well-tolerated and does not accumulate in the body. The absorption, distribution, metabolism, and excretion of tromethamol would be influenced by the formulation in which it is included, and specific pharmacokinetic parameters have not been defined in the literature.

Pregnancy

Tromethamol should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Consult healthcare professionals for advice.

Breast-feeding

It is unknown whether tromethamol is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Mechanism of action

Ketorolac inhibits key pathways in prostaglandin synthesis which is crucial to it's mechanism of action. Although ketorolac is non-selective and inhibits both COX-1 and COX-2 enzymes, it's clinical efficacy is derived from it's COX-2 inhibition. The COX-2 enzyme is inducible and is responsible for converting arachidonic acid to prostaglandins that mediate inflammation and pain. By blocking this pathway, ketorolac achieves analgesia and reduces inflammation. Ketorolac is administered as a racemic mixture; however, the "S" enantiomer is largely responsible for it's pharmacological activity.

Pharmacodynamics

Ketorolac is a non-selective NSAID and acts by inhibiting both COX-1 and COX-2 enzymes which are normally responsible for converting arachidonic acid to prostaglandins. The COX-1 enzyme is constitutively active and can be found in platelets, gastric mucosa, and vascular endothelium. On the other hand, the COX-2 enzyme is inducible and mediates inflammation, pain and fever. As a result, inhibition of the COX-1 enzyme is linked to an increased risk of bleeding and risk of gastric ulceration, while the desired anti-inflammatory and analgesic properties are linked to inhibition of the COX-2 enzyme. Therefore, despite it's effectiveness in pain management, ketorolac should not be used long-term since this increases the risk of serious adverse effects such as gastrointestinal bleeding, peptic ulcers, and perforations.